Secukinumab in plaque psoriasis—results of two phase 3 trials
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. METHODS: In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), we randomly assigned 738 patients (in the ERASURE study) and 1306 patients (in the FIXTURE study) to subcutaneous secukinumab at a dose of 300 mg or 150 mg (administered once weekly for 5 weeks, then every 4 weeks), placebo, or (in the FIXTURE study only) etanercept at a dose of 50 mg (administered twice weekly for 12 weeks, then once weekly). The objective of each study was to show the superiority of secukinumab over placebo at week 12 with respect to the proportion of patients who had a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) and a score of 0 (clear) or 1 (almost clear) on a 5-point modified investigator's global assessment (coprimary end points). RESULTS: The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 81.6% with 300 mg of secukinumab, 71.6% with 150 mg of secukinumab, and 4.5% with placebo; in the FIXTURE study, the rates were 77.1% with 300 mg of secukinumab, 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo (P<0.001 for each secukinumab dose vs. comparators). The proportion of patients with a response of 0 or 1 on the modified investigator's global assessment at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 65.3% with 300 mg of secukinumab, 51.2% with 150 mg of secukinumab, and 2.4% with placebo; in the FIXTURE study, the rates were 62.5% with 300 mg of secukinumab, 51.1% with 150 mg of secukinumab, 27.2% with etanercept, and 2.8% with placebo (P<0.001 for each secukinumab dose vs. comparators). The rates of infection were higher with secukinumab than with placebo in both studies and were similar to those with etanercept. CONCLUSIONS: Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov numbers, NCT01365455 and NCT01358578, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An Ab targeting IL-17 (secukinumab) was approved in 2016 to treat moderate-severe plaque psoriasis [54].”
From The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney (2016) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V. R., Zhang, H.-G., Wang, T., Zheng, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.08.001 · Cited by 1,026
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease
Onishi, R. M., & Gaffen, S. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03240.x · Cited by 894
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Harper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., & Blauvelt, A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.65 · Cited by 508
Cited by
Items 401–500 of 1,001
Cui, L., Chen, R., Subedi, S., Yu, Q., Gong, Y., Chen, Z., & Shi, Y. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.020 · Cited by 73
“Currently, several biological agents targeting IL-17 and IL-23 were licensed for use in the USA and Europe, such as Secukinumab [8], Brodalumab [9], Ixekizumab [10], Ustekinumab [11, 12], Guselkumab [13], and Tildrakizumab [14].”
Bianchi, E., & Rogge, L. (2019) · Genes and Immunity · doi:10.1038/s41435-019-0067-y · Cited by 69
Armstrong, A. W., Fahrbach, K. R., Leonardi, C. L., Augustin, M., Neupane, B., Kazmierska, P., Betts, M. B., Freitag, A. P., Kiri, S., Taieb, V., et al. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00760-8 · Cited by 73
“The direct downstream inhibition of IL-17A cytokines has been also shown to be a clinically effective strategy, as demonstrated by the therapeutic benefit of secukinumab and ixekizumab in moderate to severe PSO [39, 52].”
BackgroundSong, M., Liang, J., Wang, L., Li, W., Jiang, S., Xu, S., Tang, L., Du, Q., Liu, G., Meng, H., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110757 · Cited by 74
Sticherling, M., Mrowietz, U., Augustin, M., Thaçi, D., Melzer, N., Hentschke, C., Kneidl, J., Sieder, C., & Reich, K. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15707 · Cited by 64
Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors
Fieldhouse, K. A., Ukaibe, S., Crowley, E. L., Khanna, R., O’Toole, A., & Gooderham, M. (2020) · Drugs in Context · doi:10.7573/dic.2020-2-1 · Cited by 70
Elyoussfi, S., Thomas, B. J., & Ciurtin, C. (2016) · Rheumatology International · doi:10.1007/s00296-016-3436-0 · Cited by 63
“The ERASURE and JUNCTURE RCTs showed significant increase in PASI75 response and Modified-IGA response of 0 or 1 (indicating clear or almost clear psoriatic disease) versus placebo at week 12 [82, 83].”
MethodGómez-García, F. J., Epstein, D. M., Isla-Tejera, B., Lorente, A., García-Nieto, A. J. V., & Ruano, J. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14814 · Cited by 67
Revisiting Asian chronic rhinosinusitis in the era of type 2 biologics
Yao, Y., Zeng, M., & Liu, Z. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.14065 · Cited by 73
Fauber, B. P., René, O., Deng, Y., DeVoss, J., Eidenschenk, C., Everett, C., Ganguli, A., Gobbi, A., Hawkins, J., Johnson, A. R., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00597 · Cited by 70
Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis
Ovejero-Benito, M. C., Muñoz‐Aceituno, E., Reolid, A., Saiz‐Rodríguez, M., Abad‐Santos, F., & Daudén, E. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0322-9 · Cited by 68
Dreesen, E., Bossuyt, P. J., Mulleman, D., Gils, A., & Pascual‐Salcedo, D. (2017) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s138414 · Cited by 63
Redefining the therapeutic objective in psoriatic patients candidates for biological therapy
Carretero, G., Puig, L., Carrascosa, J. M., Ferrándiz, L., Ruíz‐Villaverde, R., de la Cueva, P., Belinchón, I., Vilarrasa, E., del Rio, R., Sánchez‐Carazo, J. L., et al. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1395794 · Cited by 69
“In the FIXTURE and ERASURE secukinumab studies, the PASI 75 and the modified IGA response rates increased from week 12 to week 16 and then stabilized after week 16 (15).”
BackgroundBiosimilar Drugs for Psoriasis: Principles, Present, and Near Future
Carrascosa, J. M., Jacobs, I. A., Petersel, D. L., & Strohal, R. (2018) · Dermatology and Therapy · doi:10.1007/s13555-018-0230-9 · Cited by 68
Yasmeen, N., Sawyer, L., Malottki, K., Levin, L., Apol, E. D., & Jemec, G. B. E. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1743811 · Cited by 68
GILZ regulates Th17 responses and restrains IL-17-mediated skin inflammation
Jones, S. A., Perera, D., Fan, H., Russ, B. E., Harris, J., & Morand, E. F. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.05.010 · Cited by 70
Ixekizumab for the treatment of psoriasis: up-to-date
Craig, S., & Warren, R. B. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1729736 · Cited by 64
IL-36 in chronic inflammation and cancer
Neurath, M. F. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.006 · Cited by 72
van den Reek, J. M. P. A., van Vugt, L. J., van Doorn, M. B. A., van der Kraaij, G. E., Kort, W., Lucker, G. P. H., Horváth, B., Njoo, M. D., Bovenschen, H. J., Ossenkoppele, P. M., et al. (2018) · Acta Dermato Venereologica · doi:10.2340/00015555-2900 · Cited by 62
“In the FIXTURE trial, Candida infections occurred in 5% of patients treated according to the label regimen, but all Candida events resolved spontaneously or with standard treatment, and none led to discontinuation of the study drug (3).”
Warren, R. B., Gooderham, M., Burge, R. T., Zhu, B., Amato, D. A., Liu, K. H., Shrom, D., Guo, J., Brnabic, A. J. M., & Blauvelt, A. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.038 · Cited by 62
Leonardi, C. L., Reich, K., Foley, P. A., Torii, H., Gerdes, S., Guenther, L., Gooderham, M., Ferris, L. K., Griffiths, C. E. M., Elmaraghy, H., et al. (2020) · Dermatology and Therapy · doi:10.1007/s13555-020-00367-x · Cited by 67
Tollenaere, M. A. X., Hebsgaard, J. B., Ewald, D. A., Lovato, P., Garcet, S., Li, X., Pilger, S., Tiirikainen, M. L., Bertelsen, M., Krueger, J. G., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20090 · Cited by 73
Biologic Therapy for Psoriatic Arthritis
Mease, P. J. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.07.010 · Cited by 61
Autoimmune aspects of psoriasis: Heritability and autoantigens
Prinz, J. C. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.011 · Cited by 71
Fujiyama, T., Ito, T., Umayahara, T., Ikeya, S., Tatsuno, K., Funakoshi, A., Hashizume, H., & TOKURA, Y. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.03.048 · Cited by 63
The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients
Abrouk, M. E., Nakamura, M., Zhu, T. H., Farahnik, B., Koo, J. Y. M., & Bhutani, T. (2016) · Journal of Dermatological Treatment · doi:10.1080/09546634.2016.1278198 · Cited by 61
“2% of patients at week 12, and with brodalumab even up to 70% out to week 120 (18,19).”
BackgroundThe role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target
Koga, T., Ichinose, K., Kawakami, A., & Tsokos, G. C. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1593141 · Cited by 66
Blauvelt, A., Sofen, H. L., Papp, K. A., Gooderham, M., Tyring, S. K., Zhao, Y., Lowry, S., Mendelsohn, A. B., Parno, J. R., & Reich, K. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15862 · Cited by 60
New treatments for inflammatory rheumatic disease
Selmi, C. F., Generali, E., Massarotti, M. S., Bianchi, G., & Scirè, C. A. (2014) · Immunologic Research · doi:10.1007/s12026-014-8565-5 · Cited by 66
“The results of two Phase III trials on psoriasis were recently published and showed that secukinumab is effective in the treatment of psoriasis [106].”
BackgroundRamonda, R., Lorenzin, M., Carriero, A., Chimenti, M. S., Scarpa, R., Marchesoni, A., Lubrano, E., Salvarani, C., Cauli, A., Semeraro, A., et al. (2021) · RMD Open · doi:10.1136/rmdopen-2020-001519 · Cited by 59
Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide
Liu, S., Desharnais, J., Sahasrabudhe, P. V., Jin, P., Li, W., Oates, B. D., Shanker, S., Banker, M. E., Chrunyk, B. A., Song, X., et al. (2016) · Scientific Reports · doi:10.1038/srep26071 · Cited by 62
Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases
Nirula, A., Nilsen, J., Klekotka, P. A., Kricorian, G., Erondu, N., Towne, J. E., Russell, C. B., Martin, D. A., & Budelsky, A. (2016) · Rheumatology · doi:10.1093/rheumatology/kew346 · Cited by 63
Lacour, J. ‐., Paul, C. F., Jazayeri, S., Papanastasiou, P., Xu, C., Nyirady, J., Fox, T., & Papavassilis, C. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14073 · Cited by 59
Elewski, B. E., Puig, L., Mordin, M., Gilloteau, I., Sherif, B. N., Fox, T., Gnanasakthy, A., Papavassilis, C., & Strober, B. E. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1294727 · Cited by 59
“Patient enrollment criteria and study design for the two randomized, double-blind, placebo-controlled, parallel-group, multicenter phase 3 trials (ERASURE and FIXTURE) have previously been described in detail (17).”
BackgroundInfluentialSparber, F., Dolowschiak, T., Mertens, S., Lauener, L., Clausen, B. E., Joller, N., Stoitzner, P., Tussiwand, R., & LeibundGut-Landmann, S. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007069 · Cited by 59
Warren, R. B., See, K., Burge, R. T., Zhang, Y., Brnabic, A. J. M., Gallo, G., Garrelts, A., & Egeberg, A. (2019) · Dermatology and Therapy · doi:10.1007/s13555-019-00337-y · Cited by 64
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Mease, P. J., & McInnes, I. B. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0031-5 · Cited by 58
“compared with placebo, etanercept, and ustekinumab in phase III trials [50, 51].”
ResultProbiotics for oral and vulvovaginal candidiasis: A review
Shenoy, A., & Gottlieb, A. (2019) · Dermatologic Therapy · doi:10.1111/dth.12970 · Cited by 59
“The ERASURE/FIXTURE trials for secukinumab reported a higher rate of candidiasis in the secukinumab group compared to the etanercept group and controls (Langley et al., 2014).”
BackgroundCharacterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis
Pinter, A., Gerdes, S., Papavassilis, C., & Reinhardt, M. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1626973 · Cited by 61
Augustin, M., Lambert, J., Zema, C. L., Thompson, E. H. Z., Yang, M. H., Wu, E. Q., García-Horton, V., Geng, Z., Valdes, J. M., Joshi, A. D., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.3617 · Cited by 61
Saran, A., Nishizaki, D., Lippman, S. M., Kato, S., & Kurzrock, R. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.01.002 · Cited by 71
Reich, K., Blauvelt, A., Armstrong, A. W., Langley, R. G. B., Fox, T., Huang, J., Papavassilis, C., Liang, E. C. Z., Lloyd, P. M., & Bruin, G. J. M. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14965 · Cited by 64
Self-citationKim, K. H., Hur, J. Y., Cho, J., Ku, B. M., Koh, J., Koh, J., Sun, J., Lee, S., Ahn, J. S., Park, K., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1722023 · Cited by 69
Wu, S., Xu, Y., Yang, L., Guo, L., & Jiang, X. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294416 · Cited by 69
Wride, A. M., Chen, G. F., Spaulding, S. L., Tkachenko, E., & Cohen, J. M. (2024) · Dermatologic Clinics · doi:10.1016/j.det.2024.02.001 · Cited by 69
Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases
Seremet, T., Di Domizio, J., Girardin, A., Yatim, A., Jenelten, R., Messina, F., Saidoune, F., Schlapbach, C., Bogiatzi, S., Minisini, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54559-6 · Cited by 57
Th17 Cells in Type 1 Diabetes: Role in the Pathogenesis and Regulation by Gut Microbiome
Li, Y., Liu, Y., & Chu, C. (2015) · Mediators of Inflammation · doi:10.1155/2015/638470 · Cited by 63
Byström, J., Clanchy, F. I. L., Taher, T. E. I., Mangat, P. K., Jawad, A. S., Williams, R. O., & Mageed, R. A. (2016) · Cytokine · doi:10.1016/j.cyto.2016.09.001 · Cited by 68
Burkett, P. R., & Kuchroo, V. K. (2016) · Cell · doi:10.1016/j.cell.2016.11.044 · Cited by 60
Mease, P. J., Kavanaugh, A., Reimold, A. M., Tahir, H., Rech, J., Hall, S., Geusens, P., Pellet, P., Delicha, E. M., Pricop, L., et al. (2019) · ACR Open Rheumatology · doi:10.1002/acr2.11097 · Cited by 57
“The safety profile of secukinumab was consistent with that previously reported for PsA (3,9,12–17) and psoriasis (6).”
Recapitulating T cell infiltration in 3D psoriatic skin models for patient-specific drug testing
Shin, J. U., Abaci, H. E., Herron, L., Guo, Z., Sallee, B., Pappalardo, A., Jackow, J., Wang, E. H. C., Doucet, Y., & Christiano, A. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60275-0 · Cited by 57
Burisch, J. M., Eigner, W., Schreiber, S., Aletaha, D., Weninger, W., Trauner, M., Reinisch, W., & Narula, N. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233781 · Cited by 64
“The interleukin-17 family cytokines (IL-17A to IL-17F) that signal via several IL-17 receptors (IL-17R A to E) [7, 8] are strong inducers of inflammation contributing to tissue destruction in IMIDs.”
BackgroundKoga, T., Ichinose, K., Kawakami, A., & Tsokos, G. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624971 · Cited by 69
Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders
Brummer, T., Ruck, T., Meuth, S. G., Zipp, F., & Bittner, S. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211035542 · Cited by 60
Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action
Noor, A. A. M., Azlan, M., & Redzwan, N. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020498 · Cited by 66
Dual targeting of mTOR/IL-17A and autophagy by fisetin alleviates psoriasis-like skin inflammation
Roy, T., Banang‐Mbeumi, S., Boateng, S. T., Ruiz, E. M., Chamcheu, R. N., Kang, L., King, J. A. C., Walker, A. L., Nagalo, B. M., Kousoulas, K. G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1075804 · Cited by 67
Beyond Candida albicans: Mechanisms of immunity to non-albicans Candida species
Whibley, N., & Gaffen, S. L. (2015) · Cytokine · doi:10.1016/j.cyto.2015.07.025 · Cited by 78
A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast
Chiricozzi, A., Caposiena, D. R., Garofalo, V., Cannizzaro, M. V., Chimenti, S., & Saraceno, R. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1134319 · Cited by 61
Gottlieb, A. B., Lacour, J. ‐., Korman, N. J., Wilhelm, S., Dutronc, Y., Schacht, A., Erickson, J., Zhang, L., Mallbris, L., & Gerdes, S. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13990 · Cited by 57
Kim, H. J., & Lebwohl, M. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.07.004 · Cited by 58
Zweegers, J., Groenewoud, J. M. M., van den Reek, J. M. P. A., Otero, M. E., van de Kerkhof, P. C. M., Driessen, R. J. B., van Lümig, P. P. M., Njoo, M. D., Ossenkoppele, P. M., Mommers, J. M., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.15023 · Cited by 61
Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances
Shao, S., Wang, G., Maverakis, E., & Gudjonsson, J. E. (2020) · Drugs · doi:10.1007/s40265-020-01283-2 · Cited by 64
Deshmukh, R. (2023) · Materials Today Communications · doi:10.1016/j.mtcomm.2023.105877 · Cited by 80
IL-17F Promotes Tissue Injury in Autoimmune Kidney Diseases
Riedel, J.-H., Paust, H., Krohn, S., Turner, J., Kluger, M. A., Steinmetz, O. M., Krebs, C. F., Stahl, R. A. K., & Panzer, U. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015101077 · Cited by 60
A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis
Armstrong, A. W., Bukhalo, M., & Blauvelt, A. (2016) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0206-4 · Cited by 62
“2 % with etanercept (placebo not reported) [16].”
BackgroundImmunopathology alters Th17 cell glucocorticoid sensitivity
Banuelos, J., Cao, Y., Shin, S. C., & Lu, N. Z. (2016) · Allergy · doi:10.1111/all.13051 · Cited by 58
“Psoriasis, for instance, has been successfully treated with anti-IL-17A therapy (2, 3).”
BackgroundBlauvelt, A., Papp, K. A., Lebwohl, M., Green, L. J., Hsu, S., Bhatt, V. R., Rastogi, S., Pillai, R., & Israel, R. J. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.03.026 · Cited by 59
Moderate to severe psoriasis treatment challenges through the era of biological drugs
Vide, J., & Magina, S. (2017) · Anais Brasileiros de Dermatologia · doi:10.1590/abd1806-4841.20175603 · Cited by 55
A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis
Hu, Y., Chen, Z., Gong, Y., & Shi, Y. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0603-3 · Cited by 62
Baicalin Ameliorates Imiquimod-Induced Psoriasis-Like Inflammation in Mice
Hung, C., Wang, C., Cheng, H., Liao, J., Chen, Y.-T., Chao, Y.-W., Jiang, J., & Lee, C. (2018) · Planta Medica · doi:10.1055/a-0622-8242 · Cited by 55
Hyperglycemia Is Associated with Psoriatic Inflammation in Both Humans and Mice
Ikumi, K., Odanaka, M., Shime, H., Imai, M., Osaga, S., Taguchi, O., Nishida, E., Hemmi, H., Kaisho, T., Morita, A., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.01.029 · Cited by 59
Zafiriou, E., Daponte, A., Siokas, V., Tsigalou, C., Dardiotis, E., & Bogdanos, D. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.699848 · Cited by 82
Potestio, L., Martora, F., Lauletta, G., Vallone, Y., Battista, T., & Megna, M. (2024) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s462797 · Cited by 59
“81 The ERASURE (NCT01365455) (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) study included 738 adults with moderate-to-severe plaque psoriasis who were randomized 1:1:1 to receive subcutaneous secukinumab at a dose of 300 mg or 150 mg (once a week for 5 weeks,…”
BackgroundPsoriasis as a systemic disease
Mrowietz, U., Lauffer, F., Sondermann, W., Gerdes, S., & Sewerin, P. (2024) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0064 · Cited by 54
Gaspari, A. A., & Tyring, S. K. (2015) · Dermatologic Therapy · doi:10.1111/dth.12251 · Cited by 72
“The incidence rates of AEs and SAEs in ERASURE were consistent with those of FIXTURE (26).”
MethodResultInfluentialTreatment goals for psoriasis: Should PASI 90 become the standard of care?
Torres, T. R., & Puig, L. (2014) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2014.10.001 · Cited by 60
Therapeutic implications of ‘neutrophilic asthma’
Nair, P. K., Aziz-Ur-Rehman, A., & Radford, K. (2014) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000120 · Cited by 58
Iversen, L., Eidsmo, L., Austad, J., de Rie, M. A., Osmančević, A., Skov, L., Talme, T., Bachmann, I., van de Kerkhof, P., Ståhle, M., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14979 · Cited by 59
Costanzo, A., Bianchi, L., Flori, M. L., Malara, G., Stingeni, L., Bartezaghi, M., Carraro, L., Castellino, G., & the SUPREME Study Group (2018) · British Journal of Dermatology · doi:10.1111/bjd.16705 · Cited by 54
Baraliakos, X., Østergaard, M., Gensler, L. S., Poddubnyy, D., Lee, E. Y., Kiltz, U., Martin, R., Sawata, H., Readie, A., Porter, B. O., et al. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00886-7 · Cited by 55
Lebwohl, M., Langley, R. G. B., Paul, C. F., Puig, L., Reich, K., van de Kerkhof, P., Wu, H.-L., Richter, S., Jardon, S., & Gisondi, P. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00635-4 · Cited by 53
Self-citationLangley, R. G. B., Sofen, H. L., Dei‐Cas, I., Reich, K., Sigurgeirsson, B., Warren, R. B., Paul, C. F., Szepietowski, J. C., Tsai, T., Hampele, I., et al. (2022) · British Journal of Dermatology · doi:10.1093/bjd/ljac040 · Cited by 53
Self-citationFritz, Y., Klenotic, P. A., Swindell, W. R., Yin, Z. Q., Groft, S. G., Zhang, L., Baliwag, J., Camhi, M. I., Diaconu, D., Young, A. B., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.10.021 · Cited by 53
“Published by Elsevier, Inc. on behalf of the Society for Inv IL-17-targeted inhibitors for psoriasis (Crow, 2012; Gordon et al., 2014; Langley et al., 2014; Papp et al., 2012, 2014; Silva et al., 2010).”
BackgroundPapp, K. A., Bachelez, H., Blauvelt, A., Winthrop, K. L., Romiti, R., Ohtsuki, M., Acharya, N. V., Braun, D. K., Mallbris, L., Zhao, F., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15723 · Cited by 53
Théréné, C., Brenaut, E., Barnetche, T., & Misery, L. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.05.039 · Cited by 53
Warren, R. B., Brnabic, A. J. M., Saure, D., Langley, R. G. B., See, K., Wu, J. J., Schacht, A., Mallbris, L., & Nast, A. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16140 · Cited by 59
Self-citationCytokines, growth factors and proteases in medium and large vessel vasculitis
Weyand, C. M., Watanabe, R., Zhang, H., Akiyama, M., Berry, G. J., & Goronzy, J. J. (2019) · Clinical Immunology · doi:10.1016/j.clim.2019.02.007 · Cited by 57
Erichsen, C. Y., Jensen, P. E. H., & Kofoed, K. F. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15879 · Cited by 60
Cai, L., Zhang, J.-Z., Yao, X., Gu, J., Liu, Q., Zheng, M., Zhang, S., Xu, J., Li, C., Cheng, H., et al. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001163 · Cited by 53
“Patients’ mean PASI at Baseline in the present study was approximately 21% higher than in the ERASURE trial.([16]) A criticism of the PASI 75 and PASI 90 scores is that they do not take Baseline disease severity into account, and; therefore, patients with more severe disease who achieve PASI 75/90 may still be dissati…”
BackgroundResultInfluentialTargeting cytokine networks in neuroinflammatory diseases
Becher, B., Derfuss, T. J., & Liblau, R. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01026-y · Cited by 60
“The clinical efficacy of the IL-17-blocking antibody secukinumab in improving psoriatic skin lesions was solidified in placebo-controlled phase III trials 83 .”
Loos, A. M., Liu, S., Segel, C., Ollendorf, D. A., Pearson, S. D., & Linder, J. A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.02.027 · Cited by 62
Micheroli, R., Tellenbach, C., Scherer, A., Bürki, K., Niedermann, K., Nissen, M. J., Zufferey, P., Exer, P., Möller, B., Kyburz, D., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215934 · Cited by 52
Carrascosa, J. M., Puig, L., Belinchón, I., Salgado‐Boquete, L., del Alcázar, E., Lencina, J. J. A., Moreno-Ramírez, D., & de la Cueva, P. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2021.10.003 · Cited by 68
Ryu, S., Lim, M., Kim, J., & Kim, H. Y. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01022-z · Cited by 56
“Candidate drugs are IL-17 inhibitors, which include secukinumab 159 and ixekizumab 160 .”
RORγt+ cells selectively express redundant cation channels linked to the Golgi apparatus
Drujont, L., Lemoine, A., Moreau, A., Bienvenu, G., Lancien, M., Cens, T., Guillot, F., Bériou, G., Bouchet‐Delbos, L., Fehling, H. J., et al. (2016) · Scientific Reports · doi:10.1038/srep23682 · Cited by 58
Haruta, K., Otaki, N., Nagamine, M., Kayo, T., Sasaki, A., Hiramoto, S., Takahashi, M., Hota, K., Sato, H., & Yamazaki, H. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0627 · Cited by 58
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Spindeldreher, S., Maillère, B., Correia, E., Tenon, M., Karle, A. C., Jarvis, P., & Kolbinger, F. (2018) · Dermatology and Therapy · doi:10.1007/s13555-018-0220-y · Cited by 51
van Mens, L. J. J., van de Sande, M. G. H., Menegatti, S., Chen, S., Blijdorp, I. C. J., de Jong, H. M., Fluri, I. A., Latuhihin, T. E., van Kuijk, A. W. R., Rogge, L., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40581 · Cited by 53
“In contrast to this scarcity of data with IL-17A blockade, a large number of studies with TNFi have shown their impact on tissue pathology, their efficacy in the different subtypes of the disease including peripheral SpA, and their long-term safety profile (5,6).”
InfluentialAn overview of the efficacy and safety of systemic treatments for psoriasis in the elderly
Lernia, V. G. D., & Goldust, M. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1504016 · Cited by 54
“trials (ERASURE, FIXTURE and CLEAR) [39,40] evaluating the”
MethodGuselkumab for the treatment of psoriasis – evidence to date
Nogueira, M., & Torres, T. R. (2019) · Drugs in Context · doi:10.7573/dic.212594 · Cited by 57
Metadata
- Authors
- Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T.-F., Wasel, N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., & Papavassilis, C.
- Affiliations
- Dalhousie University (CA)
- University of Alabama at Birmingham (US)
- Mount Sinai Hospital (US)
- Dermatologikum Hamburg (DE)
- Manchester Academic Health Science Centre (GB)
- Probity Medical Research (CA)
- Hospital de Sant Pau (ES)
- Jikei University School of Medicine (JP)
- University of Iceland (IS)
- National Taiwan University (TW)
- Center for Clinical Studies (US)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-24
- Volume
- 371
- Issue
- 4
- Pages
- 326-338
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1973354423
- Cited by
- 1,997
- References
- 25
- Citations by year
- 2026: 96 · 2025: 107 · 2024: 116 · 2023: 142 · 2022: 146 · 2021: 165 · 2020: 198 · 2019: 230 · 2018: 201 · 2017: 223 · 2016: 203 · 2015: 146 · 2014: 19
- FWCI
- 90.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- GRO (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- secukinumab, plaque psoriasis, IL-17A, anti-IL-17A monoclonal antibody, etanercept, PASI 75, dosing regimen, biologic therapy, treatment efficacy and safety, erasure, fixtures, Psoriasis Area and Severity Index
- MeSH terms
- Etanercept, Adult, Antibodies, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Immunoglobulin A, Immunoglobulin G, Immunosuppressive Agents, Infections, Injections, Subcutaneous, Male, Middle Aged, Psoriasis, Receptors, Tumor Necrosis Factor, Interleukin-17, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.